Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections

Executive Summary

US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up. 

You may also be interested in...



US GDUFA III Talks In Final Stages, Agreement Nearly Complete

Final commitment letter preparations now under way as revenue issues are resolved.

US FDA Gets Less FY2022 Funding From Senate Than House, Different Inspection Priorities

CDER would receive $17m less in Senate appropriations bill compared to House veion, while CFSAN's total would be nearly $10m less. Overall,  Senate bill includes around $50.4m less in funding for FDA than House bill.

FDA Would Get Less Funding, Different Inspection Priorities Under Senate Legislation Than House

CDER would lose the most money in the Senate appropriations bill compared to the House version, while CBER would see an increase.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel